CIRM Funded Clinical Trials

A Phase 1/2 Study to Assess the Safety, Tolerability, and Efficacy of ST-400 Autologous HSPC Transplant in Transfusion-dependent β-Thalassemia

Bettina Cockroft
Disease Area: 
Beta Thalassemia
CIRM Grant:
CLIN2-11031 (Closed)
Award Value:
Trial Sponsor:
Sangamo BioSciences, Inc.
Trial Stage: 
Phase 1/2
Trial Status: 
Targeted Enrollment:
5 ID:

Sangamo, Inc. is testing genetically engineered blood stem cells for the treatment of beta-thalassemia, a severe form of anemia caused by mutations in the hemoglobin gene. This genetic disorder requires life-long blood transfusions and carries a life expectancy of only 30-50 years. The Sangamo therapy takes a patient’s own blood stem cells and, using a gene-editing technology called zinc finger nuclease (ZFN), provides a functional copy of the hemoglobin gene. These modified cells are given back to the patient which potentially will eliminate the need for chronic transfusions and its associated complications.


Open label, single arm study


Safety and tolerability. Efficacy, change from baseline HbF levels, frequency and volume of RBC transfusions.